UG1EY028096
Cooperative Agreement
Overview
Grant Description
Adalimumab versus conventional immunosuppression for uveitis (ADVISE) trial.
Awardee
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Baltimore,
Maryland
212052103
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the End Date has been extended from 08/31/23 to 08/31/25 and the total obligations have increased 862% from $128,156 to $1,233,041.
The Johns Hopkins University was awarded
ADALIMUMAB VERSUS CONVENTIONAL IMMUNOSUPPRESSION FOR UVEITIS (ADVISE) TRIAL
Cooperative Agreement UG1EY028096
worth $1,233,041
from National Eye Institute in September 2018 with work to be completed primarily in Baltimore Maryland United States.
The grant
has a duration of 7 years and
was awarded through assistance program 93.867 Vision Research.
The Cooperative Agreement was awarded through grant opportunity NEI Clinical Vision Research: Chairman's Grant (UG1).
Status
(Complete)
Last Modified 8/5/24
Period of Performance
9/30/18
Start Date
8/31/25
End Date
Funding Split
$1.2M
Federal Obligation
$0.0
Non-Federal Obligation
$1.2M
Total Obligated
Activity Timeline
Subgrant Awards
Disclosed subgrants for UG1EY028096
Transaction History
Modifications to UG1EY028096
Additional Detail
Award ID FAIN
UG1EY028096
SAI Number
UG1EY028096-2793111504
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Private Institution Of Higher Education
Awarding Office
75NW00 NIH NATIONAL EYE INSTITUTE
Funding Office
75NW00 NIH NATIONAL EYE INSTITUTE
Awardee UEI
FTMTDMBR29C7
Awardee CAGE
5L406
Performance District
MD-07
Senators
Benjamin Cardin
Chris Van Hollen
Chris Van Hollen
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| National Eye Institute, National Institutes of Health, Health and Human Services (075-0887) | Health research and training | Grants, subsidies, and contributions (41.0) | $1,497,180 | 100% |
Modified: 8/5/24